Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Explore this paper's citation graph
Summary
In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
- Type
- letter
- Published
- 2017-03-17
- Cited by
- 5,096
- References
- 34
- Access
- Open access
- OpenAlex
- https://openalex.org/W2596179513
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:1972937
Keywords
Evolocumab, Medicine, Hazard ratio, Clinical endpoint, Internal medicine
References
- Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
- Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
- Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
- BASELINE LDL-C AND CLINICAL OUTCOMES WITH ADDITION OF EZETIMIBE TO STATIN IN 18,144 PATIENTS POST ACS
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
- Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
- A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.
- Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
- Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
- A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
- Unstable Angina: Is It Time for a Requiem?
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cited by
- Can LDL cholesterol be too low? Possible risks of extremely low levels
- PCSK9 inhibition in the management of familial hypercholesterolemia.
- Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis.
- Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials: more data still necessary.
- SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
- Hypercholesterolaemia – practical information for non-specialists
- A decade of genome-wide association studies for coronary artery disease: the challenges ahead
- Unexplained reciprocal regulation of diabetes and lipoproteins
- Variations in time to benefit among clinical trials of cholesterol-lowering drugs.
- Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?
- The Pleiotropic Effects of Statins – From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia
- Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
- PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
- Beyond Statins: Who and When to Prescribe?
- Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes.
- Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature.
- Measurement of Low‐Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry
- What the diabetes data in the FOURIER trial fail to show
- Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction
- Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
Related papers
- Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
- Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations
- Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.
- The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
- Update on PCSK9 Inhibitors and New Therapies
- PCSK9 Antibodies for the Treatment of Hypercholesterolemia
- PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
- PCSK9 inhibition in patients with hypercholesterolemia.
- PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies